Piper Jaffray Upgrades Acceleron Pharma (XLRN) to Overweight

Piper Jaffray analyst Danielle Brill upgraded Acceleron Pharma (NASDAQ: XLRN) from Neutral to Overweight with a price target of $75.00 (from $52.00).

The analyst says the Luspatercept opportunity has been de-risked and likes the equity noting the royalty stream remains under-appreciated.

For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.

Shares of Acceleron Pharma closed at $52.04 yesterday.

You May Also Be Interested In

• Macquarie Upgrades United Spirits Ltd. (UNITDSPR:IN) to Outperform
• JPMorgan Upgrades BOC Hong Kong (2388:HK) (BHKLY) to Overweight
• Goldman Sachs Starts SJS Enterprises Ltd (SJS:IN) at Buy